Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy
Journal of Clinical Oncology · 01.06.2026 · 44 (16) · 1557-1558
DOI: 10.1200/jco-26-00012 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.06.2026. Verfasst von Yutaka Shimazu. Beteiligte Einrichtung: Yutaka Shimazu, MD, PhD, Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 1 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Yutaka Shimazu, MD, PhD, Department of Early Clinical Development, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
ORCID-Profile: Yutaka Shimazu
Zitieren
APA
Shimazu, Y. (2026). Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology, 44(16), 1557-1558. https://doi.org/10.1200/jco-26-00012
Vancouver
Shimazu Y. Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy. Journal of Clinical Oncology. 2026;44(16):1557-1558. doi:10.1200/jco-26-00012
BibTeX
@article{Shimazu2026,
author = {Shimazu, Yutaka},
title = {Interpreting Circulating Tumor DNA-Guided Risk Stratification After First-Line Therapy},
journal = {Journal of Clinical Oncology},
year = {2026},
volume = {44},
number = {16},
pages = {1557--1558},
doi = {10.1200/jco-26-00012}
}
EUVIMED